Which telehealth services still offer compounded GLP-1s after the FDA crackdown?

The landscape for compounded GLP-1s has indeed become much more complex and scrutinized following increased warnings from the FDA. The FDA has repeatedly stated that it has not approved any compounded versions of semaglutide or tirzepatide, and has issued warnings to compounding pharmacies and telehealth platforms that market them. They emphasize concerns about safety, efficacy, and quality control with unapproved compounded drugs.

Given this heightened scrutiny, many telehealth services have either ceased offering compounded GLP-1s, significantly restricted their offerings, or pivoted to primarily prescribing the branded, FDA-approved medications (Ozempic, Wegovy, Mounjaro, Zepbound) when medically appropriate and covered by insurance.

However, some services are still known to work with compounding pharmacies to provide compounded semaglutide or tirzepatide, often emphasizing their adherence to specific compounding regulations or using specific salt forms (e.g., semaglutide sodium) which they argue are distinct enough.

Here are a couple of telehealth services that have been prominent in offering compounded GLP-1s, along with important caveats:

1. Henry Meds:

   • Why they are known: Henry Meds has been one of the most upfront and widely recognized telehealth platforms for connecting patients with providers who can prescribe compounded GLP-1s (like semaglutide or tirzepatide) from partner compounding pharmacies. They often highlight their transparent pricing and focus on access.
   • Caveat: Their continued operation in this space relies on their interpretation of compounding pharmacy regulations and their partnerships with specific pharmacies. Patients should still be aware of the FDA's general warnings regarding all compounded versions of these drugs.

2. Mochi Health:

   • Why they are known: Mochi Health also provides medical weight loss programs and has been a platform where patients can access compounded GLP-1 medications, in addition to branded options. They focus on comprehensive care including physician oversight and diet/exercise coaching.
   • Caveat: Similar to Henry Meds, their offering of compounded medications falls under the same FDA warnings and regulatory landscape.

Important Considerations for Any Telehealth Service Offering Compounded GLP-1s:

• FDA Warnings: Always remember the FDA's stance that they have not approved any compounded versions of semaglutide or tirzepatide, and they have expressed concerns about the safety, quality, and efficacy of these products. Many compounded versions use salt forms (e.g., semaglutide sodium) that have not been studied in humans in the same way as the active ingredients in the approved drugs.
• Source Pharmacy: If you consider a compounded GLP-1, inquire about the specific compounding pharmacy the telehealth service partners with. Research the pharmacy's accreditation, track record, and whether they are legitimate state-licensed pharmacies.
• Cost vs. Coverage: Compounded GLP-1s are typically paid for out-of-pocket and are not covered by insurance. While often less expensive than branded drugs without insurance, this comes with the trade-off of the lack of FDA approval.
• Medical Oversight: Ensure you are receiving care from a licensed medical professional who properly evaluates your medical history, discusses risks and benefits, and monitors your progress.
• Rapidly Changing Landscape: The regulatory environment and the offerings of telehealth services in this area are subject to rapid change. What is available today might not be tomorrow.

Recommendation:

Before pursuing any compounded GLP-1, it is highly recommended to have a detailed discussion with a trusted healthcare provider who can explain the risks and benefits of both branded and compounded medications, considering your individual health profile and the latest regulatory information. Your safety should be the top priority.